Compounding Bill In Senate Adds Office Use Provisions
This article was originally published in The Pink Sheet Daily
New version of compounding bill would allow compounders to produce limited supplies for office use, but schedule for Senate floor action remains to be seen.
You may also be interested in...
KV seeks a court order requiring FDA to desist from permitting importation of unapproved API for compounded hydroxyprogesterone and to state its intent to take enforcement action against compounders.
Ideally, the studies would be underway at the time of approval, as the US FDA’s new authority allows, but Office of Therapeutic Products Director Nicole Verdun sys there will be exceptions.
A provision in the pending legislation on PBMs that would allow the US FDA to provide qualitative and quantitative information to ANDA sponsors about reference product's inactive ingredients could save hundreds of millions in spending.